

**Data Sheet: CellGro<sup>®</sup>**  
**Recombinant Human Thrombopoietin (rh TPO)**  
**Preclinical Grade - Order No.: 1417-010, 1417-050, 1417-1000**

<b>Source</b>	A DNA sequence encoding a truncated TPO protein was expressed in <i>E. coli</i>
<b>Production</b>	Terminal manufacturing steps and QC are performed in a GMP facility
<b>Molecular mass</b>	The methionyl form of the <i>E. coli</i> expressed truncated human TPO <sub>174</sub> contains 181 amino acid residues (including an N-terminal His-6-tag) and has a molecular mass of 19.6 kDa.
<b>Purity</b>	≥ 95%, as determined by SDS-PAGE
<b>Endotoxin</b>	≤ 1000 EU/mg, as determined by LAL gel clot test
<b>Activity</b>	≥ 10 x 10 <sup>6</sup> U/mg calibrated against an internal standard Measured by proliferation of TPO-dependent MO7e cells
<b>Sterility</b>	Sterility test of the vial product (direct inoculation)
<b>Formulation</b>	Lyophilized from a 0.2 µm-filtered aqueous solution
<b>Amount per vial</b>	1417-010: 10 µg 1417-050: 50 µg 1417-1000: 1000 µg
<b>Transport</b>	Ambient temperature
<b>Storage at</b>	-20°C or below. Avoid repeated freeze-thaw cycles
<b>Expiry</b>	3 years from date of shipment

本品は研究用試薬です。治療および診断目的にはご使用できません。

**Manufacturer**

CellGenix GmbH  
Am Flughafen 16 | 79108 Freiburg | Germany  
Tel. +49 761 88889-0 | Fax +49 761 88889-830  
[www.cellgenix.com](http://www.cellgenix.com) | [info@cellgenix.com](mailto:info@cellgenix.com)

CellGro<sup>®</sup> is a registered trademark of CellGenix in several global markets. In North America and a few other countries CellGro<sup>®</sup> reagents are marketed under CellGenix<sup>™</sup>.